Statistical analysis
Results were expressed as mean±S.D.
The statistical significance of the
differences between groups was determined by one-way analysis of
variance (ANOVA) followed by Dunnett’s post hoc test analysis using the
GraphPad Prism6 software. Post hoc tests were conducted only if F was
significant, and there was no variance in homogeneity. p<0.05
was considered statistically significant.
Results
Dios treatment reduced HFD-induced body weight andblood glucose gain in KK-Ay
diabetic mice.
To
investigate the effect of Dios on body weight and blood glucose, we
conducted the KK-Ay mice that were chronically administrated with Dios
for 4 weeks. As shown in Fig. 1A, the administration of Dios
significantly reduced the body weight compared to the model group at the
end of the feeding period. Meanwhile, after 4 weeks of Dios and Met
administration, both
Dios and Met group exhibited
significantly decreased blood glucose (Fig. 1B). In addition, we found
that weight gain (Fig. 1C), adipose index (Fig. 1D, 1F) and liver index
(Fig. 1E, 1F) of Dios and Met administration were significantly lower
than that of KK-Ay diabetic mice. Those results demonstrated that Dios
reduces body weight and glucose in KK-Ay diabetic mice.
Diosameliorated
lipid accumulation in KK-Ay diabetic mice.
As
shown in Fig. 2A-2E, the serum levels of TC, TG, LDL-C were increased
and the level of HDL-C and serum insulin decreased in KK-Ay diabetic
mice compared with NC group. Notably, Dios
treatment significantly decreased
the serum levels of TC, TG, LDL-C and increased the serum level of HDL-C
and insulin. To explore the effect of Dios on preventing hepatic
steatosis, liver and skeletal muscle histopathological changes by using
H&E and oil-red staining (Fig. 2F) were performed. H&E staining of
liver sections shows widespread vacuolation in KK-Ay diabetic mice but
not in Dios and Met treated group. Moreover, fewer lipid droplets in
liver and skeletal muscles were observed in the mice of Dios treatment
as compared to the KK-Ay diabetic mice.